Enoximone
Product Specifications
UNSPSC Description
Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC50 of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits PDE4 inhibitory effect with an IC50 of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects[1][2][3].
Target Antigen
Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/enoximone.html
Purity
99.91
Solubility
DMSO : 8.33 mg/mL (ultrasonic)
Smiles
O=C1NC(C)=C(N1)C(C2=CC=C(C=C2)SC)=O
Molecular Weight
248.30
References & Citations
[1]Jan Beute, et al. A Pathophysiological Role of PDE3 in Allergic Airway Inflammation. JCI Insight. 2018 Jan 25;3(2):e94888.|[2]R C Dage, et al. Pharmacology and Pharmacokinetics of Enoximone. Cardiology. 1990;77 Suppl 3:2-13; discussion 27-33.|[3]M B Vroom, et al. Effect of Phosphodiesterase Inhibitors on Human Arteries in Vitro. Br J Anaesth. 1996 Jan;76(1):122-9.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-B1639/Enoximone-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-B1639/Enoximone-SDS-MedChemExpress.pdf
Clinical Information
Launched
CAS Number
77671-31-9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
